SAB-142 Receives FDA Fast Track Designation for New-Onset Type 1 Diabetes

SAB-142 is an experimental immunotherapy developed by SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company. The drug is a fully human anti-thymocyte immunoglobulin, a type of protein designed to modify how the immune system behaves in autoimmune disease.

The therapy is being developed specifically for people with new-onset Type 1 diabetes—those recently diagnosed and still in early disease stages. The goal is to slow or alter disease progression at a critical window when the body's immune system is actively attacking insulin-producing cells.

Fast Track designation is a regulatory pathway offered by the U.S. Food and Drug Administration for drugs targeting serious conditions where there is significant unmet medical need. This status is designed to facilitate development and speed up the review process.

The designation does not guarantee approval, but it does enable more frequent communication between the company and the FDA, and allows for priority review once data are submitted. It reflects the agency's judgment that the treatment has meaningful potential to address a real gap in available options.

SAB-142 is currently being tested in a Phase 2b clinical trial called SAFEGUARD. This study enrolls people within 100 days of a Stage 3 Type 1 diabetes diagnosis—a critical period when intervention may have the greatest impact.

Enrollment in the SAFEGUARD study is expected to be completed in the fourth quarter of 2026. Topline data from the trial are anticipated following enrollment completion, which will provide the first detailed picture of how the drug performs in this patient population.

Fast Track designation is a regulatory milestone that signals progress in the search for treatments that can modify Type 1 diabetes in its early stages. It underscores both the severity of the condition and the ongoing need for new therapeutic options.

While this designation accelerates the development pathway, it is important to note that SAB-142 remains experimental. Real-world efficacy and safety will depend on results from ongoing and completed clinical trials. The coming months will be important for gathering data on how well this approach works in newly diagnosed individuals.

Origin: GlobeNewswire News Room (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.